Related Experiment Video
Updated: Apr 15, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
Current status of chemically synthesized inhibitors of Ebola virus
Anthony P Cardile1, Douglas L Mayers, Sina Bavari
1Division of Medicine, US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702, USA. anthony.p.cardile.mil@mail.mil.
Abstract:
The current Ebola virus outbreak is unprecedented in its scope and international impact. Given that there are currently no approved antivirals to treat Ebola virus, there is urgency to conduct more rapid development and evaluation of Ebola antivirals. Recently, the World Health Organization identified a number of antivirals as high priority to include AVI-6002 (AVI-7537 and AVI-7539), BCX4430, brincidofovir, favipiravir, and TKM-100802. This review describes these chemically synthesized inhibitors of Ebola virus, relevant patent development and gives an update on their current status.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Cross-reactivity
Inhibitors of Bacterial DNA Synthesis

